$51.43 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter

Brokerages predict that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will report sales of $51.43 million for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings. The lowest sales estimate is $49.70 million and the highest is $53.00 million. Vanda Pharmaceuticals reported sales of $44.28 million in the same quarter last year, which indicates a positive year-over-year growth rate of 16.1%. The business is scheduled to announce its next earnings report on Wednesday, February 13th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year sales of $191.47 million for the current financial year, with estimates ranging from $189.70 million to $193.00 million. For the next fiscal year, analysts forecast that the firm will report sales of $253.30 million, with estimates ranging from $229.00 million to $292.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a return on equity of 5.88% and a net margin of 7.06%. The business had revenue of $49.13 million during the quarter, compared to the consensus estimate of $49.44 million. During the same period in the previous year, the business earned ($0.03) EPS. The business’s quarterly revenue was up 18.9% on a year-over-year basis.

A number of research analysts recently commented on the company. Jefferies Financial Group assumed coverage on Vanda Pharmaceuticals in a research note on Thursday, November 8th. They set a “buy” rating and a $26.00 price objective for the company. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 7th. ValuEngine upgraded Vanda Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 10th. Oppenheimer restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, December 3rd. Finally, Stifel Nicolaus restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 31st. Eight analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $37.38.

Several large investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co. NY grew its stake in shares of Vanda Pharmaceuticals by 18.4% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,187 shares of the biopharmaceutical company’s stock worth $327,000 after purchasing an additional 2,671 shares in the last quarter. Virtus ETF Advisers LLC grew its stake in shares of Vanda Pharmaceuticals by 7.2% in the third quarter. Virtus ETF Advisers LLC now owns 42,777 shares of the biopharmaceutical company’s stock worth $982,000 after purchasing an additional 2,882 shares in the last quarter. MetLife Investment Advisors LLC grew its stake in shares of Vanda Pharmaceuticals by 20.0% in the second quarter. MetLife Investment Advisors LLC now owns 24,336 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 4,063 shares in the last quarter. Strs Ohio grew its stake in shares of Vanda Pharmaceuticals by 9.7% in the second quarter. Strs Ohio now owns 47,500 shares of the biopharmaceutical company’s stock worth $904,000 after purchasing an additional 4,200 shares in the last quarter. Finally, NumerixS Investment Technologies Inc grew its stake in shares of Vanda Pharmaceuticals by 92.9% in the second quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock worth $227,000 after purchasing an additional 5,700 shares in the last quarter. 99.33% of the stock is owned by institutional investors.

VNDA traded down $1.82 during trading on Monday, reaching $27.60. 652,062 shares of the company were exchanged, compared to its average volume of 771,460. The company has a market cap of $1.54 billion, a P/E ratio of -78.86, a PEG ratio of 4.00 and a beta of 0.87. Vanda Pharmaceuticals has a 52 week low of $13.30 and a 52 week high of $33.44.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Further Reading: How to use beta for portfolio diversification

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit